Staphylococcus aureus Formyl Peptide Receptor–like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent FcγR Antagonists That Inhibit IgG-Mediated Effector Functions
暂无分享,去创建一个
J. Köhl | G. Vidarsson | J. Leusen | J. V. van Strijp | J. V. D. van de Winkel | P. Boross | M. Pandey | K. V. van Kessel | Maaike Nederend | A. Stemerding | A. Kuipers | A. Weersink
[1] T. Torgerson,et al. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. , 2012, The Journal of infectious diseases.
[2] G. Pietersz,et al. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond , 2012, Nature Reviews Drug Discovery.
[3] K. Rigby,et al. Neutrophils in innate host defense against Staphylococcus aureus infections , 2011, Seminars in Immunopathology.
[4] L. Visai,et al. The Sbi Protein Is a Multifunctional Immune Evasion Factor of Staphylococcus aureus , 2011, Infection and Immunity.
[5] S. Lohse,et al. Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing , 2011, The Journal of Immunology.
[6] J. V. van Dijl,et al. A multiplex assay for the quantification of antibody responses in Staphylococcus aureus infections in mice. , 2011, Journal of immunological methods.
[7] J. Köhl,et al. Functional basis for complement evasion by staphylococcal superantigen‐like 7 , 2010, Cellular microbiology.
[8] J. Lindsay,et al. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions , 2010, BMC Microbiology.
[9] D. Patel,et al. Specificity of Staphylococcal Superantigen-Like Protein 10 toward the Human IgG1 Fc Domain , 2010, The Journal of Immunology.
[10] J. Cid,et al. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. , 2010, The Journal of infection.
[11] Kenneth G. C. Smith,et al. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications , 2010, Nature Reviews Immunology.
[12] P. Parren,et al. Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage , 2009, The Journal of Immunology.
[13] J. V. van Strijp,et al. A Homolog of Formyl Peptide Receptor-Like 1 (FPRL1) Inhibitor from Staphylococcus aureus (FPRL1 Inhibitory Protein) That Inhibits FPRL1 and FPR1 , 2009, The Journal of Immunology.
[14] Marc Parmentier,et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family , 2009, Pharmacological Reviews.
[15] P. Bruhns,et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.
[16] P. Parren,et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. , 2008, Blood.
[17] Richard B. Brown,et al. Complications of Viral Influenza , 2008, The American Journal of Medicine.
[18] Patrik Engström,et al. The Intrinsic Immunoglobulin G Endopeptidase Activity of Streptococcal Mac-2 Proteins Implies a Unique Role for the Enzymatically Impaired Mac-2 Protein of M28 Serotype Strains , 2008, Infection and Immunity.
[19] E. Feil,et al. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. , 2008, Molecular immunology.
[20] A. Mócsai,et al. Critical but Overlapping Role of FcγRIII and FcγRIV in Activation of Murine Neutrophils by Immobilized Immune Complexes12 , 2008, The Journal of Immunology.
[21] J. Köhl,et al. Staphylococcal complement evasion by various convertase-blocking molecules , 2007, The Journal of experimental medicine.
[22] J. Stavenhagen,et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization , 2007, Immunology.
[23] R. Kimberly,et al. Expression Profile of FcγRIIb on Leukocytes and Its Dysregulation in Systemic Lupus Erythematosus1 , 2007, The Journal of Immunology.
[24] J. V. van Strijp,et al. A New Staphylococcal Anti-Inflammatory Protein That Antagonizes the Formyl Peptide Receptor-Like 11 , 2006, The Journal of Immunology.
[25] G. Vidarsson,et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. , 2006, Blood.
[26] C. Hack,et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines. , 2006, Blood.
[27] T. Foster. Immune evasion by staphylococci , 2005, Nature Reviews Microbiology.
[28] Robert B Sim,et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases , 2005, Nature Immunology.
[29] P. Selvaraj,et al. Signal-Specific Activation and Regulation of Human Neutrophil Fcγ Receptors1 , 2005, The Journal of Immunology.
[30] John D. Fraser,et al. The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcαRI Binding and Serum Killing of Bacteria1 , 2005, The Journal of Immunology.
[31] W. V. van Wamel,et al. Anti-opsonic properties of staphylokinase. , 2005, Microbes and infection.
[32] J. Musser,et al. Insight of Host Immune Evasion Mediated by Two Variants of Group A Streptococcus Mac Protein* , 2004, Journal of Biological Chemistry.
[33] J. Köhl,et al. C5a Initiates the Inflammatory Cascade in Immune Complex Peritonitis1 , 2004, The Journal of Immunology.
[34] Andreas Peschel,et al. Chemotaxis Inhibitory Protein of Staphylococcus aureus, a Bacterial Antiinflammatory Agent , 2004, The Journal of experimental medicine.
[35] D. Metcalfe,et al. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. , 2004, Clinical immunology.
[36] Dennis R. Burton,et al. Human antibody–Fc receptor interactions illuminated by crystal structures , 2004, Nature Reviews Immunology.
[37] W. L. van der Pol,et al. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. , 2003 .
[38] C. Zhu,et al. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. , 2000, Blood.
[39] J. Köhl,et al. A Codominant Role of FcγRI/III and C5aR in the Reverse Arthus Reaction1 , 2000, The Journal of Immunology.
[40] J. Köhl,et al. On the role of complement and Fc γ-receptors in the Arthus reaction , 1999 .
[41] A. Conde. Staphylococcus aureus infections. , 1998, The New England journal of medicine.
[42] R. Schmidt,et al. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. , 1996, Journal of immunology.
[43] T. Whiteside,et al. Expression and function of Fc gamma RII on human natural killer cells. , 1994, Natural immunity.
[44] J. V. D. van de Winkel,et al. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. , 1993, Immunology today.
[45] M. Hulett,et al. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. , 1993, Journal of immunology.
[46] C. Grimaldi,et al. Human neutrophil Fc gamma RIIIB and formyl peptide receptors are functionally linked during formyl-methionyl-leucyl-phenylalanine-induced chemotaxis. , 1992, Journal of immunology.
[47] B. Perussia,et al. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions , 1989, The Journal of experimental medicine.
[48] J. Hall,et al. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. , 1984, Journal of immunology.
[49] J. Deisenhofer. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.
[50] J. Ravetch,et al. FcγRs in health and disease. , 2011, Current topics in microbiology and immunology.
[51] A. Mócsai,et al. Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes. , 2008, Journal of immunology.
[52] J. V. van Strijp,et al. Bacterial complement evasion. , 2007, Molecular immunology.
[53] R. Kimberly,et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. , 2007, Journal of immunology.
[54] P. Selvaraj,et al. Signal-specific activation and regulation of human neutrophil Fc gamma receptors. , 2005, Journal of immunology.
[55] N. V. van Sorge,et al. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. , 2003, Tissue antigens.
[56] J. Köhl,et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. , 2000, Journal of immunology.
[57] J. Köhl,et al. On the role of complement and Fc gamma-receptors in the Arthus reaction. , 1999, Molecular immunology.
[58] N. Hogg,et al. The human mononuclear phagocyte high‐affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1 , 1987, European journal of immunology.